From: Robert J. Bradbury (bradbury@aeiveos.com)
Date: Sat Nov 30 2002 - 11:36:24 MST
Wow, this is significant. It also will push on the efforts of Elixir
Pharmaceuticals. What the article fails to mention is that RPD3
seems to be a class I histone deacetylase -- related in function
to the sir-2 class III histone deacetylase they are working on.
(See: http://sdb.bio.purdue.edu/fly/polycomb/sir2-1.htm)
So either the "dysdifferentiation theory of aging" or the loss
of rDNA for the ribosomes (due to improper repair of DSB)
are likely to get a boost from this. Interestingly both
of those theories rest heavily on Richard Cutler's work.
The mechanism by which 4-phenylbutyrate acts on a histone
deacetylase isn't immediately obvious to me. Perhaps someone
on the list who is a better chemist may wish to comment.
Robert
On Sat, 30 Nov 2002, Randall Randall wrote:
> Per this article, "4-phenylbutyrate" is an existing drug that
> mimics the effects of CR.
>
> http://www.ctnow.com/news/custom/newsat3/hc-longevity1129.artnov29,0,5910011.story?coll=hc-headlines-newsat3
>
>
> --
> Randall Randall <randall@randallsquared.com>
> "[The] poetic justice of cause and effect compels
> respect, compassion." -- Faithless, God is a DJ.
>
This archive was generated by hypermail 2.1.5 : Wed Jan 15 2003 - 17:58:30 MST